LEO Pharma presented new tralokinumab data at EADV 2026, focusing on real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden anatomical areas.

The data package targets a clinically distinct population: patients whose disease affects regions such as the face, hands, feet or other areas where lesions carry outsized functional and psychosocial weight. High-burden-site involvement frequently drives quality-of-life impairment disproportionate to what overall severity scores such as EASI capture on their own, which is why real-world evidence in this cohort matters to prescribing dermatologists.

What did LEO Pharma present at EADV 2026?

The company's communications around the congress center on tralokinumab, its IL-13 inhibitor approved for moderate-to-severe atopic dermatitis. The new presentations add to the drug's post-approval evidence base by shifting from randomized controlled trials toward real-world outcomes — how patients actually fare in routine practice rather than in trial settings with strict inclusion criteria.

Two populations anchor the data:

• Adults with AD involving high-burden areas
• Adolescents with the same high-burden disease pattern

Both cohorts were assessed for treatment outcomes and quality-of-life measures, according to the company's congress announcement.

Why do high-burden areas matter in AD?

Atopic dermatitis on visible or functionally critical sites — the face, flexures, hands — correlates with higher itch intensity, sleep disruption, and psychological distress than equivalent body-surface-area involvement elsewhere. Patients with head-and-neck or hand dermatitis often report worse Dermatology Life Quality Index scores than their EASI or validated global assessments would predict.

For biologics, demonstrating benefit specifically in these hard-to-treat territories strengthens the case for use in patients whom clinicians consider most impaired. Real-world data complement registrational trials by capturing adherence, persistence, and outcomes in patients who would have been excluded from those trials.

What does real-world evidence add for tralokinumab?

Regulatory approval of tralokinumab rested on randomized controlled trials with structured endpoints. Post-approval real-world studies answer different questions: effectiveness over time, quality-of-life trajectories, and performance in adolescents — a population where biologic options have expanded rapidly in recent years.

By presenting real-world outcomes and quality-of-life findings at a major European dermatology congress, LEO Pharma positions tralokinumab's evidence base for everyday clinical decision-making rather than trial-protocol conditions alone.

What comes next?

The EADV 2026 presentations add to a growing body of real-world literature on IL-13 inhibition in atopic dermatitis, and dermatologists will likely look for full publication of the datasets — including baseline severity, follow-up duration, and quality-of-life instrument scores — to judge how the results translate to their own high-burden AD patients.